RxDoctor Payments Data

Alex Sherman, MD

Gastroenterology · New York, NYNPI 1578587283

Payments from drug & device makers

$124,265in general payments, 2019–2025

Across 948 payments — averaging $131.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • Phathom Pharmaceuticals, Inc.$24K
  • Genentech, Inc.$23K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$11K
  • Redhill Biopharma Inc.$5K
  • Pfizer$4K
  • plus $13K from 41 others

What the payments were for

  • Speaking & faculty fees$31,01256%
  • Travel & lodging$3,7927%
  • Food & beverage$20,24337%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$124,265 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$271,232
Medicare patients
437
Services billed
6,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate13$71,284
Humira(Cf) PenAdalimumab11$70,407
XeljanzTofacitinib Citrate11$62,602
Mesalamine35$25,969
LinzessLinaclotide27$23,132
ViberziEluxadoline12$19,182
MotegrityPrucalopride Succinate24$16,507
Dexlansoprazole DrDexlansoprazole30$11,037
ClenpiqSod Picosulf/Mag Ox/Citric Ac40$6,861
Omeprazole471$6,776
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates73$4,581
Sucralfate37$4,036
Pantoprazole Sodium150$3,050
Budesonide EcBudesonide12$2,759
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$2,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$3,870$62,60211 claims
AbbVieLinzess, Viberzi$44,512$42,31439 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,344$16,50724 claims
Ferring Pharmaceuticals Inc.Clenpiq$570$6,86140 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$11,263$2,22316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →